Search - tctmd.com

Displaying 441 - 460 of 2176

Sort: Relevancy | Date

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

News Daily News

FDA: Endologix AAA Grafts Get New Labeling That Addresses Endoleak Potential

December 06, 2022

Impella RP Mortality Rate No Longer a Concern, FDA Says

News Daily News

Impella RP Mortality Rate No Longer a Concern, FDA Says

December 05, 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

News Conference News AHA 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

November 14, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

November 2022 News Roundup

News Opinion CV Team Dispatch

November 2022 News Roundup

November 01, 2022

More Endpoints, More Problems: FDA Offers Advice for Multi-endpoint Trials

News Daily News

More Endpoints, More Problems: FDA Offers Advice for Multi-endpoint Trials

Michael O'Riordan

October 28, 2022

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

News Daily News

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

October 20, 2022

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

News Daily News

RAPID: Positive Top-line Results for Etripamil Nasal Spray in Paroxysmal SVT

October 17, 2022

FDA: New Fix Available for Medtronic’s Troubled HeartWare VADs

News Daily News

FDA: New Fix Available for Medtronic’s Troubled HeartWare VADs

Michael O'Riordan

October 17, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

News Conference News HFSA 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

Yael L. Maxwell

October 07, 2022

Big Tobacco Bets on Menthol to Hook Youth, Women, and Blacks

News Daily News

Big Tobacco Bets on Menthol to Hook Youth, Women, and Blacks

Michael O'Riordan

October 07, 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.